Bactiguard Holding AB (publ) (BACTI-B.ST)
SEK 37.2
(-2.11%)
SEK 37.2
(-2.11%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 329.7 Million SEK | 5.68% |
| 2022 | 311.99 Million SEK | 1.35% |
| 2021 | 307.83 Million SEK | 1.98% |
| 2020 | 301.87 Million SEK | 18.53% |
| 2019 | 254.67 Million SEK | 17.55% |
| 2018 | 216.65 Million SEK | -9.08% |
| 2017 | 238.28 Million SEK | -1.43% |
| 2016 | 241.74 Million SEK | -6.59% |
| 2015 | 258.8 Million SEK | -11.5% |
| 2014 | 292.41 Million SEK | -49.26% |
| 2013 | 576.27 Million SEK | 3.08% |
| 2012 | 559.03 Million SEK | 20.77% |
| 2011 | 462.88 Million SEK | 87.22% |
| 2010 | 247.23 Million SEK | -18.13% |
| 2009 | 301.96 Million SEK | -21.17% |
| 2008 | 383.04 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 326.02 Million SEK | -1.11% |
| 2024 Q3 | 347.78 Million SEK | -0.31% |
| 2024 Q2 | 348.84 Million SEK | 7.0% |
| 2023 Q3 | 316.12 Million SEK | -3.06% |
| 2023 FY | 329.7 Million SEK | 5.68% |
| 2023 Q1 | 312.29 Million SEK | 0.1% |
| 2023 Q2 | 326.11 Million SEK | 4.42% |
| 2023 Q4 | 329.7 Million SEK | 4.3% |
| 2022 Q3 | 314.53 Million SEK | 0.01% |
| 2022 FY | 311.99 Million SEK | 1.35% |
| 2022 Q1 | 314.68 Million SEK | 2.22% |
| 2022 Q4 | 311.99 Million SEK | -0.81% |
| 2022 Q2 | 314.51 Million SEK | -0.05% |
| 2021 Q2 | 315.42 Million SEK | 3.05% |
| 2021 Q3 | 299.24 Million SEK | -5.13% |
| 2021 Q4 | 307.83 Million SEK | 2.87% |
| 2021 FY | 307.83 Million SEK | 1.98% |
| 2021 Q1 | 306.08 Million SEK | 1.4% |
| 2020 Q2 | 303.14 Million SEK | -12.14% |
| 2020 Q1 | 345.04 Million SEK | 35.48% |
| 2020 Q3 | 310.55 Million SEK | 2.44% |
| 2020 Q4 | 301.87 Million SEK | -2.8% |
| 2020 FY | 301.87 Million SEK | 18.53% |
| 2019 Q2 | 284.1 Million SEK | -1.7% |
| 2019 Q1 | 289 Million SEK | 33.39% |
| 2019 Q3 | 272.26 Million SEK | -4.17% |
| 2019 Q4 | 254.67 Million SEK | -6.46% |
| 2019 FY | 254.67 Million SEK | 17.55% |
| 2018 Q3 | 223.7 Million SEK | -3.82% |
| 2018 Q2 | 232.59 Million SEK | -4.12% |
| 2018 Q1 | 242.6 Million SEK | 1.81% |
| 2018 FY | 216.65 Million SEK | -9.08% |
| 2018 Q4 | 216.65 Million SEK | -3.15% |
| 2017 Q4 | 238.28 Million SEK | -3.17% |
| 2017 Q2 | 252.04 Million SEK | -0.91% |
| 2017 Q1 | 254.35 Million SEK | 5.21% |
| 2017 FY | 238.28 Million SEK | -1.43% |
| 2017 Q3 | 246.08 Million SEK | -2.37% |
| 2016 FY | 241.74 Million SEK | -6.59% |
| 2016 Q4 | 241.74 Million SEK | -6.65% |
| 2016 Q3 | 258.95 Million SEK | 0.24% |
| 2016 Q2 | 258.33 Million SEK | -1.28% |
| 2016 Q1 | 261.69 Million SEK | 1.12% |
| 2015 FY | 258.8 Million SEK | -11.5% |
| 2015 Q4 | 258.8 Million SEK | 13.31% |
| 2015 Q3 | 228.39 Million SEK | -14.98% |
| 2015 Q2 | 268.64 Million SEK | -3.15% |
| 2015 Q1 | 277.36 Million SEK | -5.15% |
| 2014 Q1 | 599.87 Million SEK | 4.09% |
| 2014 FY | 292.41 Million SEK | -49.26% |
| 2014 Q4 | 292.41 Million SEK | -10.01% |
| 2014 Q3 | 324.95 Million SEK | -17.76% |
| 2014 Q2 | 395.14 Million SEK | -34.13% |
| 2013 Q3 | 577.88 Million SEK | -0.4% |
| 2013 Q4 | 576.27 Million SEK | -0.28% |
| 2013 FY | 576.27 Million SEK | 3.08% |
| 2013 Q1 | 563.56 Million SEK | 0.81% |
| 2013 Q2 | 580.19 Million SEK | 2.95% |
| 2012 Q3 | 598.1 Million SEK | 1.73% |
| 2012 Q2 | 587.93 Million SEK | 0.0% |
| 2012 FY | 559.03 Million SEK | 20.77% |
| 2012 Q4 | 559.03 Million SEK | -6.53% |
| 2011 Q4 | 462.88 Million SEK | 0.0% |
| 2011 FY | 462.88 Million SEK | 87.22% |
| 2010 FY | 247.23 Million SEK | -18.13% |
| 2009 FY | 301.96 Million SEK | -21.17% |
| 2008 FY | 383.04 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Acarix AB (publ) | 10.99 Million SEK | -2897.818% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 87.671% |
| ADDvise Group AB (publ) | 2.67 Billion SEK | 87.671% |
| Arcoma AB | 33.3 Million SEK | -889.941% |
| BICO Group AB (publ) | 3.26 Billion SEK | 89.901% |
| Boule Diagnostics AB (publ) | 279.9 Million SEK | -17.792% |
| CellaVision AB (publ) | 212.32 Million SEK | -55.282% |
| Clinical Laserthermia Systems AB (publ) | 14.19 Million SEK | -2222.322% |
| Chordate Medical Holding AB (publ) | 6.86 Million SEK | -4699.868% |
| C-Rad AB (publ) | 122.4 Million SEK | -169.363% |
| Duearity AB (publ) | 17.53 Million SEK | -1780.776% |
| Dignitana AB (publ) | 37.56 Million SEK | -777.632% |
| Episurf Medical AB (publ) | 19.8 Million SEK | -1565.152% |
| Getinge AB (publ) | 24.69 Billion SEK | 98.665% |
| Scandinavian Real Heart AB (Publ) | 20.6 Million SEK | -1500.462% |
| Iconovo AB (publ) | 14.55 Million SEK | -2165.373% |
| Integrum AB (publ) | 22.07 Million SEK | -1393.689% |
| Luxbright AB (publ) | 7 Million SEK | -4609.919% |
| Mentice AB (publ) | 163.55 Million SEK | -101.585% |
| OssDsign AB (publ) | 105.25 Million SEK | -213.233% |
| Paxman AB (publ) | 44.5 Million SEK | -640.749% |
| Promimic AB (publ) | 16.15 Million SEK | -1940.728% |
| Qlife Holding AB (publ) | 62.16 Million SEK | -430.329% |
| SciBase Holding AB (publ) | 21.27 Million SEK | -1449.488% |
| ScandiDos AB (publ) | 37.18 Million SEK | -786.624% |
| Sectra AB (publ) | 1.64 Billion SEK | 79.913% |
| Sedana Medical AB (publ) | 44.06 Million SEK | -648.264% |
| Senzime AB (publ) | 58.06 Million SEK | -467.812% |
| SpectraCure AB (publ) | 14.97 Million SEK | -2101.669% |
| Stille AB | 172.64 Million SEK | -90.975% |
| Vitrolife AB (publ) | 3.66 Billion SEK | 91.011% |
| Xvivo Perfusion AB (publ) | 250.56 Million SEK | -31.582% |